Nicox S.A. (NICXF)
USD 0.25
(0.0%)
USD 0.25
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 13.89 Million EUR | 685.83% |
| 2022 | -2.37 Million USD | 89.8% |
| 2021 | -23.26 Million USD | 32.4% |
| 2020 | -34.4 Million USD | -98.35% |
| 2019 | -17.34 Million USD | 21.06% |
| 2018 | -21.97 Million EUR | 46.85% |
| 2017 | -41.34 Million EUR | -43.57% |
| 2016 | -28.79 Million EUR | -1.46% |
| 2015 | -28.38 Million EUR | -30.42% |
| 2014 | -21.76 Million EUR | 58.32% |
| 2013 | -52.21 Million EUR | 32.47% |
| 2012 | -77.32 Million EUR | 16.91% |
| 2011 | -93.05 Million EUR | 13.21% |
| 2010 | -107.22 Million EUR | 27.68% |
| 2009 | -148.26 Million EUR | -64.9% |
| 2008 | -89.91 Million EUR | 37.31% |
| 2007 | -143.41 Million EUR | -165.16% |
| 2006 | -54.08 Million EUR | -52.63% |
| 2005 | -35.43 Million EUR | -51.92% |
| 2004 | -23.32 Million EUR | 41.76% |
| 2003 | -40.04 Million EUR | 29.99% |
| 2002 | -57.2 Million EUR | 17.15% |
| 2001 | -69.04 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q4 | 13.89 Million EUR | 0.0% |
| 2023 Q1 | 1.8 Million EUR | 175.98% |
| 2023 Q2 | 3.68 Million USD | 104.35% |
| 2023 FY | 13.89 Million EUR | 685.83% |
| 2022 Q2 | -10.63 Million EUR | 8.44% |
| 2022 Q4 | -2.37 Million USD | 64.75% |
| 2022 FY | -2.37 Million USD | 89.8% |
| 2022 Q1 | -11.61 Million EUR | 43.22% |
| 2022 Q3 | -6.72 Million EUR | 36.75% |
| 2021 Q3 | -24.1 Million EUR | -37.1% |
| 2021 Q1 | -20.97 Million EUR | 25.42% |
| 2021 Q2 | -17.58 Million EUR | 16.17% |
| 2021 FY | -23.26 Million USD | 32.4% |
| 2021 Q4 | -20.46 Million EUR | 15.1% |
| 2020 Q2 | -21.33 Million EUR | 9.26% |
| 2020 FY | -34.4 Million USD | -98.35% |
| 2020 Q1 | -23.5 Million EUR | -52.13% |
| 2020 Q3 | -33.39 Million EUR | -56.54% |
| 2020 Q4 | -28.12 Million EUR | 15.79% |
| 2019 Q4 | -15.45 Million EUR | 10.6% |
| 2019 FY | -17.34 Million USD | 21.06% |
| 2019 Q3 | -17.28 Million EUR | -82.19% |
| 2019 Q2 | -9.48 Million EUR | 12.63% |
| 2019 Q1 | -10.85 Million EUR | 50.59% |
| 2018 Q3 | -25.54 Million EUR | 21.7% |
| 2018 Q2 | -32.62 Million EUR | 18.84% |
| 2018 FY | -21.97 Million EUR | 46.85% |
| 2018 Q1 | -40.2 Million EUR | 2.77% |
| 2018 Q4 | -21.97 Million EUR | 13.98% |
| 2017 Q4 | -41.34 Million EUR | 15.44% |
| 2017 Q3 | -48.89 Million EUR | -139.79% |
| 2017 Q2 | -20.39 Million EUR | 6.44% |
| 2017 FY | -41.34 Million EUR | -43.57% |
| 2017 Q1 | -21.79 Million EUR | 24.32% |
| 2016 FY | -28.79 Million EUR | -1.46% |
| 2016 Q4 | -28.79 Million EUR | 11.07% |
| 2016 Q3 | -32.38 Million EUR | -164.07% |
| 2016 Q2 | -12.26 Million EUR | 12.48% |
| 2016 Q1 | -14.01 Million EUR | 50.64% |
| 2015 Q3 | -31.85 Million EUR | 3.05% |
| 2015 FY | -28.38 Million EUR | -30.42% |
| 2015 Q4 | -28.38 Million EUR | 10.9% |
| 2015 Q2 | -32.85 Million EUR | -125.32% |
| 2015 Q1 | -14.58 Million EUR | 32.99% |
| 2014 Q3 | -27.73 Million EUR | 19.98% |
| 2014 Q1 | -48.04 Million EUR | 7.99% |
| 2014 Q2 | -34.66 Million EUR | 27.86% |
| 2014 FY | -21.76 Million EUR | 58.32% |
| 2014 Q4 | -21.76 Million EUR | 21.53% |
| 2013 FY | -52.21 Million EUR | 32.47% |
| 2013 Q4 | -52.21 Million EUR | 17.92% |
| 2013 Q3 | -63.61 Million EUR | 5.42% |
| 2013 Q2 | -67.25 Million EUR | 6.53% |
| 2013 Q1 | -71.94 Million EUR | 6.95% |
| 2012 Q3 | -81.63 Million EUR | 7.69% |
| 2012 Q4 | -77.32 Million EUR | 5.28% |
| 2012 FY | -77.32 Million EUR | 16.91% |
| 2012 Q1 | -86.75 Million EUR | 6.77% |
| 2012 Q2 | -88.43 Million EUR | -1.94% |
| 2011 Q3 | -96.06 Million EUR | 1.08% |
| 2011 Q4 | -93.05 Million EUR | 3.13% |
| 2011 Q1 | -100.43 Million EUR | 6.33% |
| 2011 Q2 | -97.11 Million EUR | 3.31% |
| 2011 FY | -93.05 Million EUR | 13.21% |
| 2010 Q3 | -115.81 Million EUR | 9.79% |
| 2010 Q2 | -128.38 Million EUR | 7.32% |
| 2010 Q1 | -138.52 Million EUR | 0.0% |
| 2010 FY | -107.22 Million EUR | 27.68% |
| 2010 Q4 | -107.22 Million EUR | 7.42% |
| 2009 FY | -148.26 Million EUR | -64.9% |
| 2008 FY | -89.91 Million EUR | 37.31% |
| 2007 FY | -143.41 Million EUR | -165.16% |
| 2006 FY | -54.08 Million EUR | -52.63% |
| 2005 FY | -35.43 Million EUR | -51.92% |
| 2004 FY | -23.32 Million EUR | 41.76% |
| 2003 FY | -40.04 Million EUR | 29.99% |
| 2002 FY | -57.2 Million EUR | 17.15% |
| 2001 FY | -69.04 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 2164.214% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -1044.587% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -1278.761% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 67.532% |
| GB Sciences, Inc. | 1.74 Million USD | -695.162% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 257.174% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 150008.182% |
| Skye Bioscience, Inc. | -5.72 Million USD | 342.843% |
| Zenith Capital Corp. | 10.06 Thousand USD | -137956.439% |
| Agentix Corp. | 37.63 Thousand USD | -36821.687% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -145.982% |
| Biomind Labs Inc. | 711.4 Thousand USD | -1853.045% |
| ContraFect Corporation | -6.02 Million USD | 330.568% |
| CSL Limited | 10.52 Billion USD | 99.868% |
| CytoDyn Inc. | 20.26 Million USD | 31.428% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -3762.556% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -2132.456% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 68.011% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 68181.145% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -1398.513% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -2087.456% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 320.381% |
| SQZ Biotechnologies Company | -36.23 Million USD | 138.341% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -1515.129% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 11.857% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -519.65% |
| Mesoblast Limited | 55.85 Million USD | 75.126% |
| Marizyme, Inc. | 18.56 Million USD | 25.176% |
| Genus plc | 190.6 Million USD | 92.71% |
| Pharming Group N.V. | 109.8 Million USD | 87.347% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -1943.235% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -1102.497% |
| IMV Inc. | 7.67 Million USD | -81.135% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -152.531% |
| MultiCell Technologies, Inc. | 90.04 USD | -15430819.591% |
| ONE Bio Corp. | 9.04 Million USD | -53.694% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -7.323% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 54.526% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -594.911% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -8.491% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -9838.199% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -69835.068% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 7659.797% |
| Enzolytics Inc. | 981.65 Thousand USD | -1315.363% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.685% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 129.554% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -96.493% |
| Genscript Biotech Corporation | -1.06 Billion USD | 101.309% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -237.395% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -3357.518% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -482.305% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -8345.739% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 75948.892% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -521.424% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -10219.447% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 1992.972% |
| Helix BioMedix, Inc. | -2.57 Million USD | 640.616% |
| EV Biologics, Inc. | 1.36 Million USD | -915.665% |
| Q BioMed Inc. | 4.06 Million USD | -242.216% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 31.476% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 77.052% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | -210.688% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -530.977% |
| HST Global, Inc. | 96.79 Thousand USD | -14254.344% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 1060710.687% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -6637.563% |
| Halberd Corporation | 144.72 Thousand USD | -9500.542% |
| Resverlogix Corp. | 6.45 Million USD | -115.377% |
| Cell Source, Inc. | 9.23 Million USD | -50.499% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -412.956% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | 335.364% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -6832.027% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | -537.789% |
| Kadimastem Ltd | -253.1 Thousand USD | 5589.486% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -10117.003% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -6803.714% |
| LadRx Corporation | -2.03 Million USD | 782.259% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -2087.456% |
| Affymax, Inc. | -5.59 Million USD | 348.24% |
| Itoco Inc. | 228.3 Thousand USD | -5985.719% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -180.29% |
| Mobile Lads Corp. | 484.23 Thousand USD | -2769.286% |
| International Stem Cell Corporation | 2.59 Million USD | -436.448% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 1.89 Million USD | -631.681% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 2147549.768% |
| Qrons Inc. | 351.42 Thousand USD | -3853.595% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -80.301% |
| SYBLEU INC | 473.71 Thousand USD | -2832.993% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 5666.06% |
| Rebus Holdings, Inc. | 305 Thousand USD | -4455.41% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -211.733% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -22161.388% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -537.076% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -304.601% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -62.446% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -1698.327% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 1211.52% |
| Neutra Corp. | 52.18 Thousand USD | -26523.489% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 658.216% |
| PureTech Health plc | -167.19 Million USD | 108.31% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 5773.151% |
| IXICO plc | -4.44 Million USD | 412.605% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -5.106% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 74.67% |
| CSL Limited | 10.52 Billion USD | 99.868% |
| Cellectis S.A. | -43.81 Million USD | 131.708% |